Eliglustat is Gaucher's only first-line oral therapy, cutting spleen volume 30% versus placebo in ENGAGE, at an annual WAC of $310,250.

Gaucher disease type 1 (non-neuronopathic) accounts for more than 90% of Gaucher cases and is the only form with disease-modifying therapy addressing its visceral, hematologic, and skeletal manifestations. The US market splits by mechanism. Enzyme replacement therapy (ERT) replaces deficient acid beta-glucosidase and is delivered by intravenous infusion: imiglucerase (Cerezyme, Sanofi/Genzyme, approved May 1994), velaglucerase alfa (VPRIV, Takeda, March 2010), and taliglucerase alfa (Elelyso, Pfizer, May 2012). Substrate reduction therapy (SRT) is oral and inhibits glucosylceramide synthase to lower substrate load: eliglustat (Cerdelga, Sanofi, 2014) and miglustat (Zavesca, Actelion/Janssen, 2003).

The commercial contest is route and line of therapy. Eliglustat is the only first-line oral therapy for Gaucher type 1 adults, but its label restricts use to CYP2D6 extensive, intermediate, or poor metabolizers identified by an FDA-cleared test, a genotype gate absent from ERT. In the ENGAGE trial, previously untreated patients on eliglustat had a 30% placebo-adjusted reduction in spleen volume, a 1.22 g/dL hemoglobin increase, and a 41% platelet rise at 9 months. Miglustat, approved a decade earlier, is positioned narrowly for mild-to-moderate patients for whom ERT is not an option, and now faces generic competition.

Three decades of IV incumbency now face a genotype-gated oral challenger.

Five questions this report answers:

Q1 - How do the three IV enzyme therapies and two oral substrate-reduction therapies differ on mechanism and route?

Q2 - What does eliglustat's CYP2D6 metabolizer gate mean for enzyme-replacement incumbency and switching?

Q3 - How do price, generic miglustat entry, and benefit routing shape access across this market?

Q4 - What did ENGAGE show for eliglustat's spleen volume, hemoglobin, and platelet outcomes at 9 months?

Q5 - Why does generic miglustat now function as the market's low-cost pricing anchor?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#GaucherDisease #US #CompetitiveIntelligence #AXLRx #RareDisease #PharmaMarketAccess

Live report page:  https://axlrx.ai/gaucher-disease/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/